GlaxoSmithKline plc Revenue & Financials

GlaxoSmithKline plc reported total revenue of $39.9 billion ($40.095 billion) for the fiscal year 2024, representing a 2 percent year-over-year decline at constant currency, driven primarily by the 74 percent sales collapse of the RSV vaccine Arexvy and the continued erosion of the legacy Advair franchise following its 2022 loss of exclusivity in the US market. The Specialty Medicines division, the company's primary growth engine, generated $21.5 billion ($21.56 billion), a 4 percent increase at constant currency, fueled by a 28 percent surge in Cabenuva sales to $2.1 billion and a 12 percent increase in Trelegy Ellipta revenue to $4.8 billion, which partially offset the 11 percent decline in the HIV franchise's legacy products. The Vaccines division contributed $9.0 billion ($9.06 billion), a 6 percent decline at constant currency, as the $1.9 billion in Arexvy sales was insufficient to compensate for the $4.2 billion generated by Shingrix, which faced intense competition from Sanofi's Shingrix rival and supply chain constraints in the US market. General Medicines revenue fell 8 percent to $9.4 billion ($9.44 billion), reflecting the ongoing impact of generic competition in the respiratory portfolio and the volume-based procurement price cuts in China. Despite the top-line pressure, GSK achieved a gross profit of $31.5 billion ($31.64 billion), representing a gross margin of 79 percent, an improvement of 120 basis points year-over-year, driven by the favorable product mix shift toward higher-margin specialty medicines and the realization of $850 million in manufacturing synergies following the closure of three underutilized facilities in Europe. Operating income reached $9.8 billion ($9.82 billion), resulting in an operating margin of 24.5 percent, while net income attributable to shareholders was $6.6 billion ($6.63 billion), or $0.7 per American Depositary Share (ADS), a 14 percent increase compared to FY2023, reflecting the company's disciplined cost management and the $1.2 billion gain on the sale of its remaining equity stake in the consumer healthcare joint venture. Free cash flow, a critical metric for the company's capital allocation strategy, totaled $8.6 billion ($8.67 billion), a 9 percent increase year-over-year, providing the financial flexibility to pay down $2.8 billion of net debt, fund the $3.5 billion annual dividend, and allocate $7.2 billion ($7.27 billion) to research and development. The company's balance sheet remains robust, with net debt standing at $14.5 billion ($14.54 billion) at year-end 2024, representing a net debt-to-EBITDA ratio of 1.8x, well within the company's target range of 1.5x to 2.5x. The effective tax rate for FY2024 was 19.2 percent, significantly below the statutory UK rate of 25 percent, reflecting the benefit of the company's global intellectual property structure and the utilization of foreign tax credits. Looking ahead to FY2025, management has issued guidance for constant currency revenue growth of 3 to 5 percent, driven by the anticipated launches of the long-acting respiratory biologic Exdensur and the next-generation myeloma ADC GSK-572, with operating margin expected to expand to 26 percent as the company realizes the full benefit of its $1.5 billion cost optimization program, which includes the consolidation of its global commercial headquarters in London and the outsourcing of 40 percent of its IT infrastructure to third-party providers.